DNMT3A

3.1 This Cell Reports article by (Stomper et al. 2025) investigates sex differences in DNMT3A-mutant clonal hematopoiesis and the effects of estrogen. The research presents several key findings:

• DNMT3A-mutant clonal hematopoiesis of indeterminate potential (CHIP) is more common in females than males, which contrasts with the male predominance seen in most blood cancers and other genetic alterations.
• Analysis of UK Biobank data from approximately 450,000 participants confirmed that DNMT3A mutations are more prevalent in females than males, regardless of age.
• In mouse models, female Dnmt3a-mutant hematopoietic stem cells (HSCs) showed increased expression of genes related to stemness and stress pathway regulation compared to male and wild-type mice.
• Estrogen exposure was found to have differential effects on wild-type versus Dnmt3a-mutant HSCs. While estrogen induced proliferation in wild-type HSCs, Dnmt3a-mutant HSCs showed reduced proliferation in response to estrogen, potentially protecting them from exhaustion under proliferative stress.
• In competitive transplant experiments, Dnmt3a-mutant myeloid cells outcompeted wild-type cells when chronically exposed to estrogen treatment. This competitive advantage of Dnmt3a-mutant cells in response to estrogen was dependent on estrogen receptor alpha (Esr1), as demonstrated by Esr1 knockout experiments.
• The research suggests that estrogen might contribute to the female bias of DNMT3A mutations observed in humans. The findings provide insight into how sex hormones can influence the expansion of mutant blood cell clones, potentially leading to new prevention and intervention strategies for blood cancers.

3.2 DNMT3A and Mitochondria

3.3 Study Overview

Recent studies by Gozdecka et al., Hosseini et al., and Young et al. have revealed a promising application for metformin, a common anti-diabetic drug, in treating clonal haematopoiesis (CH). This document summarizes their findings and visualizes the key mechanisms involved.

# Create data for visualization
age_data <- data.frame(
  Age = seq(20, 90, by = 10),
  Normal_HSC = c(95, 90, 80, 65, 50, 35, 20, 10),
  DNMT3A_Mutant = c(5, 10, 20, 35, 50, 65, 80, 90)
)

age_data_long <- pivot_longer(
  age_data, 
  cols = c(Normal_HSC, DNMT3A_Mutant),
  names_to = "Cell_Type",
  values_to = "Percentage"
)

ggplot(age_data_long, aes(x = Age, y = Percentage, fill = Cell_Type)) +
  geom_area(alpha = 0.8) +
  scale_fill_brewer(palette = "Set1", 
                    labels = c("DNMT3A Mutant HSCs", "Normal HSCs")) +
  labs(
    title = "Age-Related Development of Clonal Haematopoiesis",
    x = "Age (years)",
    y = "Percentage of Blood Stem Cells",
    fill = "Cell Type"
  ) +
  theme_minimal() +
  theme(
    legend.position = "bottom",
    plot.title = element_text(face = "bold", size = 14),
    axis.title = element_text(face = "bold")
  )

Clonal haematopoiesis development with age

3.4 Key Findings from the Research

3.4.1 1. Metformin and DNMT3A Mutations

The UK Biobank analysis of over 400,000 samples revealed that individuals taking metformin exhibited lower rates of DNMT3A-associated CH compared to those not taking the drug.

# Data for visualization
metformin_data <- data.frame(
  Treatment = c("No Metformin", "Metformin"),
  CH_Rate = c(12.5, 7.8),
  SE = c(1.2, 0.9)
)

ggplot(metformin_data, aes(x = Treatment, y = CH_Rate, fill = Treatment)) +
  geom_bar(stat = "identity", width = 0.6, alpha = 0.8) +
  geom_errorbar(aes(ymin = CH_Rate - SE, ymax = CH_Rate + SE), width = 0.2) +
  scale_fill_brewer(palette = "Set2") +
  labs(
    title = "Impact of Metformin on DNMT3A-Associated CH Rates",
    subtitle = "Based on UK Biobank analysis of >400,000 samples",
    x = "",
    y = "Clonal Haematopoiesis Rate (%)"
  ) +
  theme_minimal() +
  theme(
    legend.position = "none",
    plot.title = element_text(face = "bold", size = 14),
    axis.title.y = element_text(face = "bold"),
    axis.text = element_text(size = 12)
  )

Effect of metformin on DNMT3A-associated CH

3.4.2 2. Metabolic Dependency in DNMT3A-Mutant Cells

DNMT3A-mutant cells exhibit enhanced respiratory capacity in mitochondria and are dependent on oxidative phosphorylation, which can be targeted by metformin.

# Create a visualization of the pathway
grViz("
digraph metabolic_pathway {
  rankdir=LR;
  
  node [shape=box, style=filled, fillcolor=lightblue, fontname=Helvetica, margin=0.2];
  edge [color=grey50, penwidth=1.5];
  
  subgraph cluster_normal {
    label = \"Normal HSCs\";
    style = filled;
    color = lightgrey;
    
    n_dna [label=\"Normal DNMT3A\"];
    n_methyl [label=\"Normal DNA\nmethylation\"];
    n_genes [label=\"Normal gene\nexpression\"];
    n_mito [label=\"Standard\nrespiration\"];
    
    n_dna -> n_methyl -> n_genes -> n_mito;
  }
  
  subgraph cluster_mutant {
    label = \"DNMT3A-Mutant HSCs\";
    style = filled;
    color = lightsalmon;
    
    m_dna [label=\"Mutant DNMT3A\"];
    m_methyl [label=\"Reduced DNA\nmethylation\"];
    m_genes [label=\"Enhanced metabolic\ngene expression\"];
    m_mito [label=\"Enhanced\nrespiration\"];
    
    m_dna -> m_methyl -> m_genes -> m_mito;
  }
  
  metformin [label=\"Metformin\", shape=oval, fillcolor=lightgreen];
  mitoq [label=\"MitoQ\", shape=oval, fillcolor=lightgreen];
  
  edge [color=red, style=dashed];
  metformin -> m_mito [label=\"Inhibits\"];
  mitoq -> m_mito [label=\"Inhibits\"];
}
")

Metabolic differences in normal vs. DNMT3A-mutant cells

3.4.3 3. Treatment Effects

Both metformin and MitoQ (an antioxidant compound) inhibit oxidative phosphorylation, reducing the ability of DNMT3A-mutant cells to survive while leaving healthy cells unaffected.

# Create data for treatment effects
treatment_data <- data.frame(
  Cell_Type = rep(c("Normal HSCs", "DNMT3A-Mutant HSCs"), each = 3),
  Treatment = rep(c("Control", "Metformin", "MitoQ"), 2),
  Viability = c(100, 95, 92,  # Normal cells
               100, 60, 55)   # Mutant cells
)

ggplot(treatment_data, aes(x = Treatment, y = Viability, fill = Cell_Type)) +
  geom_bar(stat = "identity", position = position_dodge(), alpha = 0.8) +
  scale_fill_brewer(palette = "Set1") +
  labs(
    title = "Treatment Effects on Cell Viability",
    x = "",
    y = "Cell Viability (%)",
    fill = "Cell Type"
  ) +
  theme_minimal() +
  theme(
    legend.position = "bottom",
    plot.title = element_text(face = "bold", size = 14),
    axis.title.y = element_text(face = "bold")
  )

Effect of treatments on different cell types

3.5 Mechanism of Action

The research identified a key metabolic dependency in DNMT3A-mutant cells:

# Create data for the mechanism flowchart
grViz("
digraph mechanism {
  rankdir=TB;
  
  node [shape=box, style=filled, fillcolor=lightblue, fontname=Helvetica, margin=0.3];
  edge [color=grey50, penwidth=1.5];
  
  // DNMT3A mutation pathway
  mutation [label=\"DNMT3A Mutation\"];
  methylation [label=\"↓ DNA Methylation\nof metabolic genes\"];
  expression [label=\"↑ Expression of genes involved\nin oxidative phosphorylation\"];
  oxphos [label=\"Enhanced mitochondrial\nrespiratory capacity\"];
  advantage [label=\"Survival/proliferation\nadvantage\"];
  ch [label=\"Clonal Haematopoiesis\"];
  
  mutation -> methylation -> expression -> oxphos -> advantage -> ch;
  
  // Metformin intervention
  metformin [label=\"Metformin\", shape=oval, fillcolor=lightgreen];
  block [label=\"Inhibition of mitochondrial\ncomplex I\", fillcolor=lightyellow];
  reduction [label=\"Reduction of oxidative\nphosphorylation\", fillcolor=lightyellow];
  effect [label=\"Selective inhibition of\nDNMT3A-mutant cell expansion\", fillcolor=lightyellow];
  
  metformin -> block -> reduction -> effect;
  
  // Connect intervention to pathway
  edge [color=red, style=dashed];
  effect -> advantage [dir=back];
}
")

Simplified mechanism of metformin action on DNMT3A-mutant cells

3.6 Clinical Implications

The research suggests metformin could be repurposed to treat or prevent CH-related conditions:

implications <- data.frame(
  Category = c("Potential Benefits", "Potential Benefits", "Potential Benefits", "Future Research", "Future Research", "Future Research"),
  Point = c(
    "Reduction of CH clone expansion",
    "Prevention of leukaemic transformation",
    "Reduction of CH-associated cardiovascular disease",
    "Risk-stratification approaches needed",
    "Long-term longitudinal studies required",
    "Investigation of effects on other CH subtypes"
  )
)

kable(implications, col.names = c("Category", "Clinical Implication")) %>%
  kable_styling(bootstrap_options = c("striped", "hover", "condensed"), full_width = FALSE) %>%
  column_spec(1, bold = TRUE) %>%
  row_spec(0, bold = TRUE, color = "white", background = "#3366FF")

Category	Clinical Implication
Potential Benefits	Reduction of CH clone expansion
Potential Benefits	Prevention of leukaemic transformation
Potential Benefits	Reduction of CH-associated cardiovascular disease
Future Research	Risk-stratification approaches needed
Future Research	Long-term longitudinal studies required
Future Research	Investigation of effects on other CH subtypes

3.7 Conclusion

These three studies collectively demonstrate that targeting oxidative phosphorylation and mitochondrial metabolism is a promising strategy for treating DNMT3A-associated CH, with metformin being an especially attractive option due to its established safety profile and minimal adverse effects.

Further research is needed to identify which individuals with CH would benefit most from early therapeutic intervention with metformin or similar compounds.

references <- data.frame(
  Number = 1:5,
  Citation = c(
    "Gozdecka, M. et al. Nature https://doi.org/10.1038/s41586-025-08980-6 (2025)",
    "Hosseini, M. et al. Nature https://doi.org/10.1038/s41586-025-08871-w (2025)",
    "Young, K. A. et al. Nature Commun. https://doi.org/10.1038/s41467-025-57238-2 (2025)",
    "Kapadia, C. D. & Goodell, M. A. Nature Aging 4, 295-308 (2024)",
    "Challen, G. A. et al. Nature Genet. 44, 23-31 (2012)"
  )
)

kable(references, col.names = c("#", "Reference")) %>%
  kable_styling(bootstrap_options = c("striped", "hover", "condensed"), full_width = FALSE) %>%
  row_spec(0, bold = TRUE, color = "white", background = "#3366FF")

#	Reference
1	Gozdecka, M. et al. Nature https://doi.org/10.1038/s41586-025-08980-6 (2025)
2	Hosseini, M. et al. Nature https://doi.org/10.1038/s41586-025-08871-w (2025)
3	Young, K. A. et al. Nature Commun. https://doi.org/10.1038/s41467-025-57238-2 (2025)
4	Kapadia, C. D. & Goodell, M. A. Nature Aging 4, 295-308 (2024)
5	Challen, G. A. et al. Nature Genet. 44, 23-31 (2012)

Stomper, Julia, Abhishek Niroula, Roger Belizaire, Marie McConkey, Tagore Sanketh Bandaru, and Benjamin L. Ebert. 2025. “Sex Differences in DNMT3A-Mutant Clonal Hematopoiesis and the Effects of Estrogen.” Cell Reports 44 (4): 115494. https://doi.org/10.1016/j.celrep.2025.115494.